DME patients fare better with Eylea compared to laser photocoag

In a Phase 3 clinical trial comparing the safety and efficacy of Regeneron Pharmaceuticals' (NASDAQ:REGN) Eylea (aflibercept) to laser photocoagulation in patients with diabetic macular edema, those receiving injections of Eylea showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100.

Study subjects receiving Eylea 2 mg every month had a mean change in BCVA from baseline of 11.4 letters (mean change at 52 weeks was 10.5 letters). Subjects receiving Eylea 2 mg every 2 months after receiving five monthly injections showed a mean change in BCVA from baseline of 9.4 letters (down from 10.5 letters at 52 weeks). Subjects receiving laser coagulation showed a mean change in BCVA from baseline of 0.7 letters (1.2 letters at 52 weeks).

31.1% of the Eylea test group dosed every 2 months achieved an increase of at least 15 letters (~3 lines of vision) compared to 38.2% of the Eylea group dosed monthly compared to 12.1% of the laser group.

The two-year data will be presented at upcoming medical conferences.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs